Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results

Rhea-AI Summary

Legend Biotech (NASDAQ: LEGN) will host an investor conference call and live audio webcast at 8:00 a.m. ET on Tuesday, August 11, 2026, to review its second quarter 2026 financial results. Senior management will provide an overview of the company’s quarterly financial performance.

According to Legend Biotech, investors and interested parties can access the live webcast via a provided weblink, with a replay and the earnings press release available about two hours after the call in the Investor Relations section of its website under Events and Presentations.

Market Context

Comparable conference-and-earnings-date announcements averaged -1.61% over five events. This notice ...

Analysis

Comparable conference-and-earnings-date announcements averaged -1.61% over five events. This notice schedules results without reporting figures; the platform record adds a negative historical pattern, while recent insider activity was Net Selling.

Key Figures

Reporting period: Second quarter 2026 Conference call time: 8:00 a.m. ET Conference call date: August 11, 2026 +2 more

5 metrics

Reporting period Second quarter 2026 Financial results to be reviewed

Conference call time 8:00 a.m. ET August 11, 2026 investor call

Conference call date August 11, 2026 Investor conference call

Replay availability Two hours After the conclusion of the call

Employees Over 3,000 employees Company description

Previous Conferences,earnings date Reports

5 past events · Latest: Apr 28 (Neutral)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 28	Q1 results call	Neutral	-0.4%	Scheduled Q1 2026 results call; shares declined 0.38% over 24 hours.
Feb 24	Q4 results call	Neutral	-1.3%	Scheduled Q4 and full-year results call; shares declined 1.27% over 24 hours.
Oct 29	Q3 results call	Neutral	-1.4%	Scheduled Q3 2025 results call; shares declined 1.35% over 24 hours.
Jul 28	Q2 results call	Neutral	-4.3%	Scheduled Q2 2025 results call; shares declined 4.27% over 24 hours.
Apr 29	Q1 results call	Neutral	-0.8%	Scheduled Q1 2025 results call; shares declined 0.78% over 24 hours.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

All five tag-matched conference and earnings-date announcements were followed by negative 24-hour reactions, averaging -1.61%.

Key Terms

car-t, cell therapy, multiple myeloma

3 terms

car-t medical

"forefront of the CAR-T cell therapy revolution"

CAR-T is a type of cancer therapy that reprograms a patient’s own immune cells to seek and destroy specific cancer cells, like teaching guard dogs a new scent to track intruders. It matters to investors because CAR-T treatments can command high prices, drive strong revenue for successful developers, and carry regulatory and manufacturing risks that can sharply affect a company’s valuation and long-term growth prospects.

cell therapy medical

"a global leader in cell therapy"

Cell therapy uses living human or animal cells as the medicine: cells are collected, sometimes grown or altered, and then given to a patient to repair, replace, or boost damaged tissue or immune function. For investors, cell therapies can transform markets because they may offer one-time or highly effective treatments that command premium prices, but they also carry high development, manufacturing and regulatory costs and commercial risks, like building a custom factory rather than making a simple product.

multiple myeloma medical

"relapsed or refractory multiple myeloma"

A cancer of the blood that starts in plasma cells, the immune system’s antibody-producing cells in bone marrow. It behaves like a factory where the workers go rogue, crowding out healthy cells and causing bone damage, anemia and infections; treatments and trial results can sharply affect drug sales, regulatory approvals and company valuations, so progress or setbacks are closely watched by investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRIDGEWATER N.J., July 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m. ET on Tuesday, August 11, 2026, to review second quarter 2026 financial results.

During the conference call and accompanying webcast, senior management will provide an overview of quarterly financial performance.

Investors and other interested parties may access the live audio webcast via this weblink.

A replay of the webcast, along with the earnings press release, will be available in the Investor Relations section of the Legend Biotech website under Events and Presentations approximately two hours after the conclusion of the call.

ABOUT LEGEND BIOTECH

With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI^®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Learn more at https://legendbiotech.com and follow us on X, Instagram, and LinkedIn.

INVESTOR CONTACT:
Caroline Paul
Tel: (973) 650-5832
Caroline.Paul@legendbiotech.com

PRESS CONTACT:
Kim Fox
Tel: (848) 388-8445
media@legendbiotech.com

FAQ

When is Legend Biotech (NASDAQ: LEGN) reporting second quarter 2026 results?

Legend Biotech will review its second quarter 2026 results on a conference call at 8:00 a.m. ET on August 11, 2026. According to Legend Biotech, senior management will present an overview of quarterly financial performance during the call and webcast.

How can investors listen to the Legend Biotech Q2 2026 earnings conference call?

Investors can listen to the Legend Biotech Q2 2026 earnings call via a live audio webcast accessible through a weblink. According to Legend Biotech, the webcast link will be available on the company’s Investor Relations website under Events and Presentations.

Will a replay be available for Legend Biotech’s August 11, 2026 earnings call?

Yes, a replay of Legend Biotech’s August 11, 2026 earnings webcast will be available. According to Legend Biotech, the replay and the earnings press release will appear in the Investor Relations section under Events and Presentations about two hours after the call.

What will Legend Biotech management discuss on the Q2 2026 LEGN investor call?

Legend Biotech management will provide an overview of the company’s quarterly financial performance for Q2 2026. According to Legend Biotech, senior leaders will review second quarter 2026 financial results during the scheduled conference call and accompanying webcast.

Where can I find Legend Biotech’s Q2 2026 earnings press release for LEGN?

The Q2 2026 earnings press release will be available in Legend Biotech’s Investor Relations website section. According to Legend Biotech, it will be posted under Events and Presentations about two hours after the earnings call concludes.

Who is the investor relations contact for Legend Biotech (LEGN)?

Legend Biotech lists Caroline Paul as its investor contact, reachable at (973) 650-5832 and Caroline.Paul@legendbiotech.com. According to Legend Biotech, she handles investor-related inquiries for the company’s financial communications and events.